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Beckwith–Wiedemann syndromeBeckwith–Wiedemann syndrome (BWS) is an overgrowth syndrome associated with genetic or epigenetic alter-
ations in one of two imprinted domains on chromosome 11p15.5. Rarely, chromosomal translocations or inversions
of chromosome 11p15.5 are associated with BWS but the molecular pathophysiology in such cases is not under-
stood. In our series of 3 translocation and 2 inversion patients with BWS, the chromosome 11p15.5 breakpoints
map within the centromeric imprinted domain, 2. We hypothesized that either microdeletions/microduplications
adjacent to the breakpoints could disrupt genomic sequences important for imprinted gene regulation. An alternate
hypothesis was that epigenetic alterations of as yet unknown regulatory DNA sequences, result in the BWS pheno-
type. A high resolutionNimblegen custommicroarraywas designed representing all non-repetitive sequences in the
telomeric 33 Mb of the short arm of human chromosome 11. For the BWS-associated chromosome 11p15.5 trans-
locations and inversions, we found no evidence of microdeletions/microduplications. DNA methylation was also
tested on this microarray using the HpaII tiny fragment enrichment by ligation-mediated PCR (HELP)
assay. This high-resolution DNA methylation microarray analysis revealed a gain of DNA methylation in
the translocation/inversion patients affecting the p-ter segment of chromosome 11p15, including both
imprinted domains. BWS patients that inherited a maternal translocation or inversion also demonstrated
reduced expression of the growth suppressing imprinted gene, CDKN1C in Domain 2. In summary, our
data demonstrate that translocations and inversions involving imprinted domain 2 on chromosome
11p15.5, alter regional DNA methylation patterns and imprinted gene expression in cis, suggesting that
these epigenetic alterations are generated by an alteration in “chromatin context”.
© 2011 Elsevier Inc. All rights reserved.1. Introduction
Beckwith–Wiedemann syndrome (BWS) is an overgrowth disorder
involving macroglossia, omphalocele, and an increased risk (1000-fold)
of embryonal tumors [1–3]. This condition is associated with dysregula-
tion of gene expression in an imprinted gene cluster on chromosome
band 11p15.5 (Fig. 1). The chromosome 11p15.5 region houses two
imprinteddomains, each controlled by an imprinting center (IC). Imprint-
ing centers are characterized by differential, parent of origin-speciﬁc
methylation. Regulation of imprinted genes also involves non-coding
RNA transcripts that regulate the expression of neighboring genes in cisabolicGenetics, TheHospital for
5G 1X8. Fax: +1 416 813 5345.
rights reserved.over distances up to one megabase [4–6]. Molecular changes observed
in patients with BWS include both genetic and/or epigenetic alterations
on chromosome11p15.5 [7, 8]. The epigenetic alterations include changes
inDNAmethylation or histonemodiﬁcations in at least one of the two im-
printing centers (IC1, IC2) [8–10].
In Domain 1, IC1 is associated with the genes H19 (a non-coding
RNA of unknown function) and insulin-like growth factor 2 (IGF2)
(Fig. 1). Gain of methylation at the maternal IC1 accounts for 5% of
BWS cases [11], with repression of the maternal H19 transcript and
de-repression of the maternal IGF2 transcript [12].
In Domain 2, IC2 overlaps the 5′ region of KCNQ1OT1, a non-coding
RNA found within intron 10 of the KCNQ1 gene [13]. Also in this domain
are several other imprinted genes implicated in BWS, including the
CDKN1C gene, a cyclin-dependent kinase inhibitor. KCNQ1OT is a pater-
nally expressed, non-coding RNA, which downregulates the expression
Fig. 1. Schematic map of the 11p15.5 region. A) Schematic representation of the chromosome 11p15.5 imprinted cluster from the UCSC genome browser coordinate
chr11:1900000–3000000 (http://genome.ucsc.edu). The 11p15.5 imprinted cluster is divided into two domains (Domain 1 is telomeric, while Domain 2 is more centromeric)
with an imprinting center for each Domain. Biallelically expressed genes are shown in black. Maternally expressed imprinted genes are noted by red text color and paternally
expressed imprinted genes are noted by blue text color. Direction and approximate length of the transcript are indicated by arrows. IC1 is a differentially methylated region up-
stream of the H19 transcription start site. IC2 is a differentially methylated region upstream of the non-coding RNA KCNQ1OT1. The approximate locations of the translocation
breakpoints are shown on the map based on previously published mapping [19, 25, 26] and validated by our BAC FISH studies. B) The IC1 differentially methylated region in detail.
The location of the H19 transcript is noted by the red arrow (maternal expression) and the location of CpG islands and the H19 DMR are shown by green and yellow boxes respec-
tively. The location of the seven putative CTCF binding sites are shown by small blue boxes and the location of the targets for pyrosequencing and Southern assays are indicated.
C) The IC2 differentially methylated region in detail. The location of the KCNQ1OT1 transcript is noted by the blue arrow (paternal expression) and the location of CpG island and the
KCNQ1OT1 DMR is shown by green and yellow boxes respectively. The location of the targets for the pyrosequencing and Southern assays is indicated. The KCNQ1 (maternally
expressed) transcript passes through this region in the antisense orientation although there is no coding sequence as this region is contained within intron 10 of KCNQ1.
26 A.C. Smith et al. / Genomics 99 (2012) 25–35of nearby genes on the paternal chromosome e.g. KCNQ1 and CDKN1C [5,
14] (Fig. 1). Loss of maternal methylation of IC2 is seen in 50% of patients
with sporadic BWS [2, 7, 15, 16]. Deletion of the orthologous sequence in
mouse results in loss of imprinting of several neighboring genes including
KCNQ1, indicating that this IC is critical for maintaining imprinted gene
expression in Domain 2 [4]. In humans, loss of methylation at the mater-
nal IC2 on chromosome 11p15.5 has been shown to be associated with
reduction of CDKN1C expression, thereby explaining the pathophysiology
of such cases of BWS [5]. Other genetic alterations associated with BWS
include paternal uniparental disomy (UPD) of chromosome 11 (~20%),
mutations in the CDKN1C gene (5–10%), and microdeletions involving
IC1 (~5%) and infrequently microduplications of IC2 (b1%) [17, 18].
In b1% of BWS cases, cytogenetically visible chromosomal changes
are associated with the BWS phenotype. These include paternally
transmitted duplications of chromosome 11p15.5 and maternally
transmitted translocations or inversions [19–27]. Unbalanced chro-
mosome rearrangements involving chromosome 11p15.5 alter the
copy number of imprinted genes thereby presumably changing the
dosage of growth regulatory genes such as IGF2 and CDKN1C.
BWS patients with maternally transmitted, apparently balanced
translocations or inversions of chromosome 11p15.5 exhibit typical
features of BWS. The mechanism by which such balanced transloca-
tions and inversions of the imprinted cluster on 11p15.5 result in
the BWS phenotype is not understood. In the case of such balanced
rearrangements there are no known associated changes in copy num-
ber and all the translocations/inversions are maternally inherited.
The cause of the BWS phenotype in apparently balanced translo-
cations and inversions is not clear. FISH mapping studies haveindicated that the chromosome 11p15.5 translocation and inversion
breakpoints cluster near the KCNQ1 gene — encompassing a region
of over 400 kilobases. Such BWS-associated translocations and inver-
sions also demonstrate breakpoints that lie several megabases cen-
tromeric to KCNQ1 (such as sample B10.1 in [19]). No alterations in
single copy genomic sequences have been reported in these appar-
ently balanced translocation and inversions. We hypothesized that
position effects over large distances, leading to altered expression of
genes in the 11p15.5 imprinted cluster, might result in BWS.
However, recent literature indicates that chromosomal rearrange-
ments that are apparently balanced by standard cytogenetic methods
may involve unexpected complexity when investigated using high
resolution technologies [20, 21]. Therefore we proposed an alterna-
tive hypothesis that microdeletion/microduplication of regulatory el-
ements when passed through the maternal germline could lead to the
BWS phenotype. Further, since apparently balanced translocations
and inversions only produce a BWS phenotype upon maternal trans-
mission, we also hypothesized that an epigenetic mark that could not
be reset in the female germline could cause the BWS phenotype.
Through molecular investigations of the latter possibility, cis-acting
elements important in the establishment or maintenance of imprint-
ing on chromosome 11p15.5, could be discovered.
We report here that translocations and inversions disrupting the cen-
tromeric imprinted domain on chromosome 11p15.5 are not associated
with microdeletions or microampliﬁcations, but can result in regional
changes in DNA methylation. Further, we show that dysregulation of
the maternally expressed growth suppressing gene, CDKN1C, occurs in
patients with BWS that have a maternally derived translocation or
27A.C. Smith et al. / Genomics 99 (2012) 25–35inversion. We conclude that 11p15.5 translocations and inversions can
alter DNAmethylation several megabases away from the primary break-
points, causing dysregulation of imprinted gene expression that results
in the BWS phenotype.2. Results
2.1. Translocation and inversion breakpoint conﬁrmed by FISH
The patient samples tested in our study are shown in Table 1. Each
translocation and inversion was given a unique code. Samples for clini-
cally unaffected parents are identiﬁed by a “U” and affected probands
by an “A”. Translocations are designated with a “T” and inversions by
“INV”. Each unique rearrangement is designated by either a U for an un-
affected parent and/or an A for an affected child, each with the same pu-
tative rearrangement e.g. T1U is a translocation in an unaffected
individual; T1A is considered to be the same rearrangement in an affect-
ed individual. For some samples we have lymphoblastoid and ﬁbroblast
cell lineswhich are indicated in Table 1. In an effort to be consistent with
previously published studies, we have also listed in Table 1, the names of
the translocations or inversions as they appeared in previous
publications.
Clinical features for patient INV1A includemacroglossia,macrosomia,
ear creases/pits and omphalocele. Cells from patient INV2A with mild
macroglossia and an omphalocele with an extracorporeal liver were
obtained at the time of pregnancy termination. Patient T1A had macro-
glossia, ear creases/pits, organomegaly, neonatal hypoglycemia and an
umbilical hernia. Although this series is small, it is worth noting that
macroglossia, ear creases and omphalocele are clinical features common-
ly seen in patients withmolecular defects in domain 2 including CDKN1C
mutations [22].
Since most of the mapping studies on these translocation/inversion
breakpoints pre-dated the completion of the human genome sequence,
we wanted to reﬁne the location of the breakpoints using clones that
map to the KCNQ1 region on chromosome band 11p15.5.
Using four previously published mapping studies [19, 23–26] and
our own FISH mapping with RP-11 library BAC clones, we conﬁrmed
the relative breakpoint locations of the translocations and inversions
in our study samples (Fig. 1A). We chose four RPCI-11 BAC library
clones that spanned the 400 kb KCNQ1 gene from 5′ to 3′ (RP11-
542J6, RP-11-373H8, RP11-38L8 and RP11-81K4).
INV1U is an unaffected mother with a pericentric inversion inv(11)
(p15.5,q13) inherited from her father [27]. INV1A is the daughter of
INV1U and is affected with BWS. This inversion produces a split signal
by FISH using the RP11-81K4 clone conﬁrming that the breakpoints in
the 3′ end of KCNQ1 are in the region chr11:2,755,275-2,927,014
(171,740 base pairs). INV2A is a proband affected with BWS for whom
we did not have parental material. The breakpoint for INV2A is also in
the 3′ end of KCNQ1. This paracentric inversion does not include the
q-arm as in INV1 as the breakpoint is inv(11)(p11.2,q15.5). This inver-
sion produces a split signal by FISH using the RP11-38L8 clone in theTable 1
Translocation and inversion patients.
Patient sample Cell type Karyotype
INV1U Fibroblast Inv(11) (p15.5; q13), pat
INV1A Fibroblast Inv(11) (p15.5; q13), mat
INV2A Fibroblast inv(11) (p11.2;p15.5), mat
T1U Lymphoblast t(11;22) (p15.5;q11.23)
T1A Lymphoblast t(11;22) (p15.5;q11.23) ma
T1A-F Fibroblast t(11;22) (p15.5;q11.23) ma
T2 Lymphoblast t(11;16) (p15.5;q12)
TM-87 Rhabdoid Tumor Line t(11;22) (p15.5;q12.23)region chr11:2,624,682-2,805,692 (181,011 base pairs) and is within
50 kb of the differentially methylated region IC2. T1U is an unaffected
mother with a translocation between chromosomes 11 and 22, t
(11;22)(q15.5;q11.23). T1A, her affected child, has the same transloca-
tion by cytogenetic analysis. This translocation showed a split signal
using the FISH probe RP11-373H8 indicating the break point is in the re-
gion chr11:2,261,657-2,468,447 (205,791 base pairs). For T1A we have
two available tissues — a lymphoblastoid cell line and a ﬁbroblast cell
line (T1A-F) derived from resected tongue tissue. T2U is an unaffected
mother carrying a translocation t(11;16)(q15.5;q12) and typical features
of BWS. She had a child with translocation who died in the neonatal pe-
riod. TM-87 is a rhabdoid tumor cell line derived from a patient that did
not have BWS. The TM-87 translocation breakpoints were determined
to be t(11;22)(q15.5;q12.23) [19, 24, 28]. Both T1 and TM87 involve
chromosome 22 with a breakpoint on band q11.23 for T1, just distal to
the 22q11deletion syndrome region, andbandq12.23 for TM87, for a dis-
tance of 8 megabases between these two breakpoints.2.2. Maintenance of DNA methylation at IC1 and IC2
2.2.1. IC2 methylation
Since the BWS-associated translocations cluster around IC2 (within
300 kilobases on either side of IC2), we looked for loss of methylation at
IC2 and biallelic expression of KCNQ1OT1, as is seen in approximately
50% of BWSpatients.Monoallelic expression ofKCNQ1OT1was detected
for all samples with informative transcribed single nucleotide polymor-
phisms (data not shown). Surprisingly, an investigation of DNAmethyl-
ation at IC2 showed normal methylation for all cases except one
(Fig. 2A). In only one case, INV2A,was themethylation at the KCNQ1OT1
IC disrupted on transmission through the maternal germline. In the in-
version patient, INV2A previously named CV581 [19, 23], with the
breakpoint very close to the KCNQ1OT1 IC methylation was absent on
both alleles (Fig. 2A) [19]. Methylation results obtained by pyrosequen-
cingwere conﬁrmed by Southernblotting (data not shown). Theseﬁnd-
ings indicate that regulatory elements other than the KCNQ1OT1
promoter region (IC2) or its transcript can regulate imprinting on chro-
mosome 11p15.5 to produce the BWS phenotype. For INV2A, loss of
methylation at IC2 could account for the BWS phenotype, in line with
the usual mechanism presumed in BWS with loss of methylation at
IC2 and without translocations or inversions, that KCNQ1OT1 is
expressed biallelically and causes a downregulation of CDKN1C likely
due to a change in the chromatin structure of the region [5, 10].2.3. Differential IC1 methylation (H19 promoter and differentially
methylated region)
Less than 10 percent of our patients with BWS have gain of meth-
ylation of the differentially methylated region associated with IC1 and
the H19 promoter. Investigation of DNA methylation at the H19 IC1 of
all ﬁve affected individuals showed normal methylation for allPreviously published Previous name
Squire et al. 2000 INV11
Hoovers et al. 1995 CV581
Weksberg et al. 1993, Squire et al. 2000 T1
t Weksberg et al. 1993, Squire et al. 2000 T1
t Weksberg et al. 1993, Squire et al. 2000 T1
Weksberg et al. 1993 T2
Karnes 1991, Hoovers et al. 1995, Lee et al.
1997, Lee et al. 1999
TM-87
A) DNA methylation of IC2
B) DNA methylation of IC1
Fig. 2. DNA methylation analysis of IC2 and IC1 by pyrosequencing. A) DNA methylation of the differentially methylated promoter of KCNQ1OT1 (IC2) was assayed by pyrosequen-
cing. The average DNA methylation of 5 CpG sites in the differentially methylated region was tested and is shown for each sample tested in duplicate with standard deviations in-
dicated by the error bars. All samples showed normal methylation except for sample INV2A which showed a complete loss of methylation. BWIC2 is patient with BWS, normal
Karyotype, and a loss of methylation at IC2. All pyrosequencing results correspond directly with methylation-sensitive Southern blotting results for the same region (data not
shown). B) DNA methylation of the differentially methylated IC1 region upstream of the H19 gene was assayed by pyrosequencing. The average DNA methylation of 3 CpG sites
in the differentially methylated region was tested and is shown with standard deviations for each sample tested. All samples showed normal methylation (~50%) and were
done in duplicate. BWIC1 is a sample from a patient with BWS that has a normal Karyotype and gain of methylation at the H19 IC1 region. All pyrosequencing results were consis-
tent with methylation-sensitive Southern blotting for the same region.
28 A.C. Smith et al. / Genomics 99 (2012) 25–35samples tested at the sixth putative CTCF binding site in the differen-
tially methylated region by pyrosequencing (Fig. 2B).
2.4. Reduced CDKN1C gene expression in patients with BWS and
translocations or inversions
Using ﬁbroblast cells derived from INV1U (inv(11)(q15.5,q13)),
INV1A (inv(11) (q15.5, q13)), and TM-87t((11;22)(p15.5;q12.23)),
we assessed total transcription of CDKN1C by qRT-PCR. We found
that this imprinted gene is downregulated in INV1A and TM-87 pre-
sumably as a result of the translocations, but independently of IC2
DNA methylation and expression of the non-coding RNA KCNQ1OT1(Fig. 3). The extent of this downregulation is equivalent to that ob-
served in a ﬁbroblast strain with loss of methylation at IC2 and con-
comitant downregulation of CDKN1C (BW1; Fig. 3). CDKN1C is
expressed at very low levels in lymphoblastoid cell lines and there-
fore could not be tested in other translocation/inversion samples.
2.5. IGF2 expression is not altered in patients with BWS and
translocations or inversions
Using ﬁbroblast cell lines expression of IGF2was also assessed. We
did not ﬁnd increased expression of IGF2 above control levels of ex-
pression in any of our samples (data not shown).
Fig. 3. Reduced CDKN1C expression in translocation and inversion samples with BWS.
Real-time PCR for CDKN1Cwas performed on ﬁbroblast samples since CDKN1C expression
is not detectable in lymphoblasts. Expression of CDKN1Cwas normalized to that of house-
keeping genes GAPDH, HPRT1 and YWHAZ according to the method published by Vande-
sompele et al. [43]. INV1U, an unaffected mother, shows normal expression of CDKN1C
whereas INV1A and TM-87 show reduced expression of CDKN1C. Five normal ﬁbroblast
control samples were tested for comparison to the expression of the BWS patients. BW1
is a ﬁbroblast line from a patient with BWS that has loss of methylation at IC2 and
shows reduced expression of CDKN1C usually seen in BWS patients with this lesion.
29A.C. Smith et al. / Genomics 99 (2012) 25–352.6. No microduplications or microdeletions detectable by microarray in
BWS-associated translocation/inversion breakpoints
We developed a custom array covering 33,000,000 base pairs of se-
quence from the 11pter segment of chromosome 11 to chromosome
band 11p13 (chr11:1–33,000,000; hg18 Mar 2006) using Nimblegen's
custom array platform. Using 300,000 features on the 385,000 feature
Nimblegen custom microarray of 11pter, we represented this region at
an average resolution of 58 bp between consecutive probes. Repetitive
sequences were not represented on the array as they cross-hybridize at
many genomic locations. We used the array CGH to test our hypothesis
that microdeletions ormicroduplicationsmay have occurred duringma-
ternal transmission. The detection of copy number variations was mini-
mized by our study design because we used a pooled reference DNA
(Promega, Madison, WI.). However, very small changes in copy number
were still detected as demonstrated by the detection of a segmental du-
plication (located at chr11:10486286–10488459; hg18Mar 2006) of ap-
proximately 2 kb in size. We tested the two translocation and inversion
pedigrees for which we had matched tissue samples from both the
mother and affected proband (INV1U/INV1A – ﬁbroblast, T1U/T1A –
lymphoblastoid cell lines). Despite the high level of resolution on our
microarrays, we were unable to detect any microdeletions or microdu-
plications associated with the breakpoint regions in the affected pro-
bands. This indicates that the breakpoint regions are apparently
balanced and do not show any rearrangement complexity. Although
breakpoints could be altered within adjacent individual repetitive
sequence elements, any single copy microdeletions or microduplica-
tions would have to be very small (b58 bp) to escape detection by
our custom array. We conclude that these rearrangements are not
associated with signiﬁcant microdeletions or microduplications.
2.7. Regional gain of DNA methylation in BWS patients with
translocations and inversions
In addition to the 300,000 features for array CGH we also analyzed
85,000 features for methylation using the HELP assay representing
approximately 10,000 locations [29] on the distal 33 Mb of chromo-
some 11p. For analysis, samples were used from pedigrees in which
a maternal transmission of the translocation or inversion had oc-
curred, provided we had the same tissue available for parent and off-
spring. In this way, tissue-speciﬁc methylation differences would beminimized in the analysis. In order to analyze methylation differences
across samples and tissues, we compared the variability forMspI rep-
resentations among all arrays. The MspI representation represents all
the potential cut sites for MspI regardless of whether they are meth-
ylated and therefore a high correlation validates our expectations.
All arrays showed coefﬁcients of determination (R2) above 0.90 for
all the analyzed lymphoblast (CNL1, CNL2, T1U, T1A) and ﬁbroblast
(CNF1, CNF2, INV1U, INV1A, INV2A) samples. This conﬁrms previous-
ly published results for this technique [29] and shows that the repre-
sentation of the methylation-insensitive enzyme MspI is consistent
among samples. Correlation coefﬁcients between HpaII and MspI/
HpaII ratios are, as expected, lower as methylation differences
among tissues and also methylation between, affected and control
samples are reﬂected in this value (R2 range=0.4983–0.9235).
We observed that global patterns of DNA methylation were con-
sistent among cell lines as seen in Fig. 4A. Most CpGs in the human
genome are methylated with the notable exception of CpGs that are
in CpG islands [30–34]. Our samples also showed hypomethylation
of CpG-containing promoters and general hypermethylation of sur-
rounding sequences (data not shown).
Our hypothesis that chromosome 11p15.5 translocations and inver-
sions cause BWS in affected probands after maternal transmission due
to an alteration in one or more speciﬁc methylated sub-regions of chro-
mosome 11p15.5 was not supported. DNAmethylation in translocation
and inversion ﬁbroblast samples is altered over very large genomic dis-
tances likely as a result of the translocation or inversion itself (Fig. 4B).
Methylation values for control ﬁbroblasts were averaged and then all
methylation values were subtracted from the control average to aid in
the visualization of changes in DNAmethylation in translocation and in-
version patients. INV1A and INV2A showed DNA gain of methylation
throughout the BWS imprinted cluster from 1.9 Mb to 3.0 Mb. They
also showed gain ofmethylation at 11, 16, 21–22 and 30–31 Mb. In con-
trast the unaffected mother, INV1U, showed regions of loss of methyla-
tion especially at 5, 16, 21–27 and 29–31 Mb illustrating that
chromosomal rearrangements have long-range effects on DNAmethyl-
ation. The gain of methylation in the BWS imprinted cluster is seen in
the ﬁbroblasts of both patients with BWS. Lymphoblast samples from
BWS cases with translocations were also studied for changes in DNA
methylation, but did not demonstrate the epigenetic alterations in
DNA methylation and CDKN1C transcription observed in ﬁbroblasts
(data not shown). Analysis of CpG islandmethylation in gene promoter
regions, represented on the array, shows that the majority of CpG
islands located near a gene promoter were unmethylated (Fig. 5).
There are 408 CpG islands in the ﬁrst 33 megabases of chromosome
11. Of these, 110 were located near a gene promoter for which DNA
methylation datawas available. Across all samples, >50% of CpG islands
were unmethylated. A small number of CpG islandsweremethylated in
a tissue-speciﬁc manner, i.e. completely unmethylated in lymphoblasts
andmethylated in ﬁbroblasts or vice versa. Further, several CpG islands
represented on the array and located in the ﬁrst 4 megabases of chro-
mosome 11 appeared to have variable patterns of DNA methylation
among samples, indicating that DNA methylation may not be tightly
regulated in these speciﬁc regions for this particular tissue. No CpG is-
land within the imprinted cluster on chromosome 11p15.5 showed a
methylation change speciﬁc to the affected probands in either the ﬁbro-
blast or lymphoblast samples that were tested.
3. Discussion
Translocations and inversions involving theKCNQ1 gene on chromo-
some 11p15.5 are associated with Beckwith–Wiedemann syndrome.
Maternal transmission of this rearrangement induces a regional gain
of DNAmethylation (Fig. 4B) and changes in imprinted gene expression
(Fig. 3). We demonstrated that long-range epigenetic defects on chro-
mosome 11p15.5 occurring in these patients can downregulate the
transcription of the growth suppressor gene, CDKN1C.
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Fig. 4. BWS-associated translocations and inversions disrupt DNA methylation in ﬁbroblasts. A) DNA methylation data for two control ﬁbroblast samples (CNF1 and CNF2) are
shown. DNA methylation ratios are averaged in 0.5 Mb bins and plotted on the y-axis. The ﬁrst 33 Mb of chromosome 11 are represented on the x-axis. Increased DNA methylation
is represented by a negative ratio and a loss of DNA methylation by a positive ratio. B) DNA methylation in BWS-associated chromosome 11p15.5 translocation and inversion ﬁ-
broblast samples is shown. Control ﬁbroblast methylation values have been averaged and then all methylation values were substracted by the control average. This conversion
sets the control methylation as “zero”which aids in the visualization of the changes in DNAmethylation in the translocation and inversion patients. Deviations below zero represent
DNA hypermethylation compared to controls and deviations above zero represent hypomethylation compared to controls. INV1A and INV2A show a gain of DNA methylation
throughout the BWS imprinted cluster from 1.9 Mb to 3.0 Mb (red box). They also show regions with gain of DNA methylation at 11, 16, 21–22 and 30–31 Mb. In contrast the un-
affected mother, INV1U, shows regions with loss of DNA methylation especially at 5, 16, 21–27 and 29–31 Mb illustrating that chromosomal rearrangements may have long-range
effects on DNA methylation. Gain of DNA methylation in the BWS imprinted domain on chromosome 11p15.5 is seen in all affected patients.
30 A.C. Smith et al. / Genomics 99 (2012) 25–35Although changes in DNA methylation are detected over large dis-
tances in patients with translocations and inversions, the methylation
of CpG island promoter regions remains largely unchanged. It is likely
therefore that the expression of most genes on the derivative chromo-
some 11, outside the imprinted region, is not altered. The imprinted re-
gion on chromosome 11p15.5 is likely more susceptible to position
effects for two reasons. Firstly, imprinted genes are expressed normally
from only one allele and are dosage sensitive. So any perturbation to the
active allele could substantially change the amount of transcript pro-
duced. Secondly, the expression of imprinted genes on chromosome
11p15.5 is under long-range control from at least one of the two im-
printing centers, IC1 and IC2. In fact, the maternal allele may be much
more susceptible to changes in the local chromatin environment be-
cause of the normal long-range regulation of imprinted genes exclu-
sively expressed from the maternal allele. This explains the selective
disruption of gene expression linked to maternal transmission. It
could also explain why some rare translocations that do not occur in
the KCNQ1 gene body, like B10.1t(4;11)(p15.2;p15.4) [19], can cause
BWS by generating a long-range position-effect on this region (Fig. 4B).
Recent microarray data have shown that cytogenetically balanced
translocations and inversions can have rearrangement complexity
resulting in a phenotype [20, 21]. We hypothesized that the BWS
breakpoint region may be associated with just such microdeletions
andmicroduplications. These genomic alterations could disrupt geno-
mic imprinting in this region by changing the copy number of critical
elements contained within the KCNQ1 gene. This hypothesis was not
supported by our array CGH analysis as no such genomic alterationwas detected. It is possible, however, that small gains or losses within
individual ﬂanking repetitive sequences may have been missed be-
cause no repetitive sequence was represented on the microarray.
Maternal transmission of all the identiﬁed balanced translocations
and inversions is required for the clinical manifestation of BWS in the
cases studied [19, 25–27, 35]. Although reports in the literature also
describe unbalanced rearrangements associated with BWS, such sam-
ples were intentionally excluded as the gains or losses of paternal or
maternal chromosomal material would clearly alter the balanced con-
tribution of maternal and paternal genes. Subjects without an appar-
ent imbalance of parental material were of greatest interest to look
for disruption of imprinting regulation. In the case of balanced trans-
locations and inversions the pathogenesis of BWS could result from
one of two distinct processes. The ﬁrst possibility is that the translo-
cations or inversions disrupting the KCNQ1 gene, separates enhancers
and chromatin regulatory elements that are crucial for the correct ex-
pression of maternally expressed genes in IC2. Since the translocation
on the paternal chromosome would not disrupt the expression of the
maternally expressed imprinted genes in most tissues it would have a
silent phenotype unless the breakpoint on the partner chromosome
of the translocated or inverted 11 disrupted another gene or regulato-
ry sequence. This would cause phenotypes or a syndrome other than
BWS. Recent reports of translocations between chromosomes 4 and
11 have shown just that-type of presentation in patients with fea-
tures of both Wolf-Hirschhorn syndrome and BWS [36].
The second possible mechanism is that translocations and inver-
sions cause a long-range position-effect altering the chromatin
Fig. 5. Changes in DNA methylation do not affect CpG islands. A) The ﬁrst 33 megabases of chromosome 11 has 405 CpG islands deﬁned by the UCSC genome browser. Gene pro-
moters that were associated with CpG islands were selected and merged with methylation microarray data using the Galaxy Bioinformatics package developed by Penn State Uni-
versity (http://galaxy.psu.edu). All 110 CpG islands that were associated with promoter regions and were represented on the array were selected. A heatmap showing the
methylation status for those CpG islands containing promoters are shown where red represents unmethylated DNA in a gradient towards blue representing methylated DNA.
The majority of CpG islands that are associated with gene promoters are unmethylated. B) Percentage of gene promoters in CpG islands that are methylated and unmethylated
in ﬁbroblast samples. There is a slight decrease in CpG promoter methylation in INV1U showing ~55% unmethylated CpG islands compared to the other samples which all show
between 65% and 70% unmethylated CpG islands. C) Percentage of gene promoters in CpG islands that are methylated and unmethylated in lymphoblast samples. CNL1 shows a
higher number of unmethylated CpG islands at 80% whereas CNL2, T1U and T1A show 65%–70% of CpG islands unmethylated.
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lating the expression of CDKN1C. This mechanism is supported by
data published by Diaz-Meyer and colleagues showing that some
cases of BWS had a closed chromatin conformation at CDKN1C inde-
pendently repressing the expression of this gene without any other
detectable genetic or epigenetic alteration [10].Since the majority of imprinted genes on chromosome 11p15.5 are
maternally expressed, the maternal chromosome may exhibit a more
open chromatin conformation relative to the paternal chromosome.
When a translocation or inversion occurs in this region (as in themoth-
er of INV1) and is then passed through the maternal germline the posi-
tion effect induced by the rearrangement could silence the normally
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along the chromosome in cis. This would be comparable to the observa-
tions of translocations involving the inactive X and autosomal chromo-
somes, where DNA methylation and chromatin conformation can be
shown to spread in cis along the chromosome.
When euchromatic regions are juxtaposed to constitutive hetero-
chromatin by a chromosomal rearrangement, spreading of the hetero-
chromatic chromatin state into the euchromatic region may cause
gene silencing. This may result from either a disruption of the normal
boundary elements that regulate chromatin domains or, perhaps, as a
consequence of maintaining functional chromatin structure. We dem-
onstrate here that translocations and inversions disrupting imprinted
domains can result in regional changes in DNA methylation and dysre-
gulation of imprinted gene transcription in a parent of origin-speciﬁc
manner resulting in disease. This supports the concept that rearrange-
ments of DNA, including translocations and inversions may cause
human disease by altering epigenetic modiﬁcation.
4. Methods
4.1. Tissue culture
Lymphoblastoid cell lines were established by Epstein–Barr virus
transformation of blood from patients diagnosed with BWS. Lines were
maintained in RPMI 1640 media with 15% fetal calf serum and 50 units
of pencillin plus 50 μg of streptomycin per mililitre at 37 °C and 5%
CO2. Fibroblast cell strains were obtained from standard punch biopsies
of tissues, surgical resections or from aborted fetuses subsequently trea-
ted with collagenase to obtain enriched cultures of ﬁbroblast cells. Cells
were passaged in alpha modiﬁed Eagle's medium with 10% fetal calf
serum and 50 units of pencillin plus 50 μg of streptomycin per mililitre
at 37 °C and 5% CO2. Fibroblast strains were not cultured beyond 10 pas-
sages to reduce the inﬂuence of any culture-related changes.
4.2. Patient samples
This study was approved by the Research Ethics Board of the Hos-
pital for Sick Children. All families gave their informed consent to par-
ticipate. Our collection consists of 8 samples with ﬁve unique
maternally derived translocations and inversions that map to the Do-
main 2 imprinted region of chromosome 11p15. The translocation
and inversion rearrangements in our sample are summarized in
Table 1. Control samples (CNF1, CNF2, CNL1, CNL2) are from healthy
individuals and have been tested for DNA methylation at imprinting
centers IC1 and IC2.
4.3. DNA extraction
DNA was extracted from lymphoblastoid and ﬁbroblast cells by
standard phenol-chloroform extraction protocol [37]. Brieﬂy, for lym-
phoblastoid cell lines, 5–20 ml of cell culture orwhole bloodwas centri-
fuged at 250×g to pellet cells. For ﬁbroblast culture cells were
harvested from culture dishes by scraping after being brieﬂy washed
with phosphate buffered saline. Nuclei were then lysed and digested
by proteinase K. Samples were then mixed with phenol and then phe-
nol/chloroform, spun in Phase Lock Gel tubes (Eppendorf, Mississauga,
Canada) and the aqueous phase decanted. DNA was then spooled and
rehydrated in TE. DNA quality was tested by gel electrophoresis and
spectrophotometry.
4.4. RNA extraction and cDNA preparation
Total RNA was extracted from lymphoblastoid cell lines and ﬁbro-
blast strains by RNeasy kit (Qiagen GmbH, Germany) according to the
manufacturer's instructions. Brieﬂy, 5 mL (approx 1,000,000 cells/mL)
or one 10 cm plate of ﬁbroblasts were suspended in buffer RLT. Aftercentrifugation of the lysate at 10,000×g for 3 min, the supernatant
was transferred to a fresh tube and mixed with an equal volume of
70% ethanol. The mixture was then transferred to the RNeasy spin col-
umn and centrifuged at 10,000×g for 15 s. The RNA was washed by
Buffer RW1 and RPE (QIAGEN®) and eluted in 30 μl RNase-free water.
Potentially contaminating DNAwas removed from the RNA samples
by DNaseI (Invitrogen, Burlington, Canada) treatment for 15 min at
room temperature followed by heat inactivation. cDNA was prepared
by Reverse-iTTM 1st strand synthesis kit (Thermo-Fisher Scientiﬁc/
ABgene, Rochester, NY) according to the manufacturer's instructions.
The ﬁrst-strand cDNA was synthesized from 2 μg of total RNA by incu-
bation with Reverse-iTTM RTase blend, random decamers, 5× ﬁrst
strand synthesis buffer, dNTP mix and DTT at 47 °C for 50 min. For
each sample, a parallel reactionwas also preparedwithout reverse tran-
scriptase to provide a control to rule out DNA contamination.
4.5. Methylation analyses—southern blotting
5–10 μg of genomic DNA was digested with EcoR1 and NotI or PstI
andMluI or PstI and SmaI for the IC2 region, IC1 region and theH19 pro-
moter, respectively. Digested DNAwas electrophoresed on 0.8% agarose
gel and transferred overnight to a positively charged nylon membrane
(Hybond N+, Amersham Biosciences, Piscataway, NJ) in 0.4 N NaOH.
Membranes were neutralized and prehybridized in modiﬁed Church's
buffer with salmon sperm DNA as a blocking agent. 32P-dCTP random
labeled probe was added overnight at 65 °C and washed with serial
washes of SSPE (2×, 1×, 0.5×, all containing 0.5% SDS). Membranes
were then exposed to Phosphor screen for at least 24 h and imaged by
Storm Phosphorimager (GE Healthcare, Piscataway, NJ). Bands were
quantitated by Fluorchem Software (Alpha-Innotech, San Leandro, CA)
by dividing the band intensity of the undigested fragment, indicating
a methylated product, by the sum of the digested and undigested frag-
ments as previously described [2, 13, 38]. Probe locations are listed in
Supplemental Table 3.
4.6. Bisulphite modiﬁcation
1 μg of DNA sample was used in the Qiagen EpiTect 96 Bisulphite
Modiﬁcation kit (Qiagen GmbH, Germany) according to the manufac-
turer's instructions. Brieﬂy, sodium bisulﬁte-mediated conversion of
unmethylated cytosines was accomplished by exposing the samples
to reaction mix containing sodium bisulphite followed by 3 cycles of
denaturation (95 °C) at 5 min for each cycle and incubation (60 °C)
of 25, 85 and 175 min for cycles 1–3. Single-stranded DNA samples
were then bound to the membrane of an EpiTect 96 Plate, washed
and desulfonated. The desulfonating agent was then removed by
washing and converted DNA was collected by elution.
4.7. Methylation analyses — pyrosequencing
Pyrosequencing (Biotage, Uppsala, Sweden) reactions for the
KCNQ1OT1 IC2 differentially methylated region (DMR), IGF2DMR,
H19 promoter, H19 enhancers and H19 DMR region were designed
using the Pyrosequencing Assay Design Software (see Fig. 1B, 1C).
PCR product of each region was used for the individual sequencing re-
action (Supplemental Table 2). The biotinylated PCR product (40 uL)
was puriﬁed using streptavidin-Sepharose beads (Amersham Biosci-
ences, Piscataway, NJ). Puriﬁcation with streptavidin-Sepharose HP
beads followed by denaturation of the biotinylated PCR products
and the sequencing primer (15 pmol per reaction) were conducted
following the PSQ 96 sample preparation guide using the pyrose-
quencing vacuum prep tool (Biotage AB). Reactions were designed
as recommended by the manufacturer's instructions with the
single-strand PCR product providing a template. After primer anneal-
ing, sequencing was carried out with a PSQ 96MA system using the
Pyrogold reagent kit according to the manufacturer's instructions.
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with the instrument. Percent methylation was calculated for the
H19 CTCF region (sixth CpG site) and IGF2 DMR by analyzing the
unmethylated and methylated peak height for each CpG analyzed.
All pyrosequencing reactions were performed using a universal bioti-
nylated primer solution previously published by Royo and colleagues
[39, 40]. Primer information for all pyrosequencing reactions is con-
tained in Supplemental Table 2.
4.8. Fluoresence in-situ hybridization
Chromosome spreads were prepared for FISH analysis according
to established cytogenetic and hybridization protocols [41]. At least
20 metaphase nuclei were analyzed from each sample using the
Vysis Quips FISH Imaging System (Vysis, Inc.). The following probes
RP-11-542J6, RP-11-373H8, RP-11-38L8 and RP-11-81K4 were end-
labeled by nick translationwith Texas Red or FITC andwere used to val-
idate the location of the translocation and inversion breakpoints. Since
many of the studies published regarding the breakpoint locations
were performed before the ﬁnal draft of the human genome sequence
was completed we wished to conﬁrm the location of each breakpoint.
4.9. Quantitative real-time RT-PCR
Quantitative real-time RT-PCRwas performed to assess CDKN1C and
IGF2 expression using the ABI Prism 7900 Sequence Detection System
(Applied Biosystems Inc., Foster City, CA)with SYBRGreen PCR incorpo-
ration. The ampliﬁcation mix (20 μl) contained a cDNA template de-
rived from 5 ng of total RNA, 200 nM or 100 nM of each speciﬁc
primer set (Supplemental Table 4), 10 μl SYBR Green Mix and RNase-,
DNase-free water. The PCR reaction was initiated by incubation at
95 °C for 10 min to activate hot-start Taq polymerase followed by 40 cy-
cles of denaturation at 95 °C for 10 s, then annealing at 60 °C for 1 min
and followed by elongation at 72 °C for 1 min. Fluorescence detection
was performed immediately following each cycle and the purity of
each ampliﬁcation product was conﬁrmed by generating dissociation
curves. For all samples, real-time RT-PCR was performed with cDNA
templates generated from reactions with and without reverse tran-
scriptase. No PCR product was observed when reverse transcriptase
was not added. Relative expression of each gene was determined
using the standard curve method [42] and normalized by the expres-
sion of the housekeeping genes GAPDH, YWHAZ and HPRT1 [43].
4.10. Allelic expression analysis by SNaPshot
Single nucleotide primer extension assay was used on the SNaP-
shot platform (Applied Biosystems, Foster City, CA) to determine
the allelic expression proﬁle for coding KCNQ1OT1 single nucleotide
polymorphisms (SNPs) [23, 44].
Reverse-transcribed PCR products (cDNA) were analyzed when pa-
tients were heterozygous for KCNQ1OT1 SNPs. Primers are listed in Sup-
plemental Table 4. Brieﬂy, DNA and cDNA amplicons encompassing SNP
siteswere treatedwith shrimpalkaline phosphatase (SAP) and subjected
to Exonuclease I (Exo) (USB) treatment. SNP genotyping was performed
using SNaPshot™ single-basepair extension reactions (Applied Biosys-
tems Inc., Foster City, CA), which contained 7 μl of cleaned PCR product
(at a concentration of 0.01 to 0.4 pmol PCR product), 2 μl of SNaPshot™
multiplex enzyme mix and 50 ng of primer for a total volume of 10 μl.
Conditions for the 25 extension reaction cycles included 96 °C for 10 s,
50 °C for 5 s and 60 °C for 30 s. 1 μl of SNaPshot reactionswas suspended
in 9 μl of Hi-Di formamide (ABI) and run on an ABI 3100 genetic analyzer
(Applied Biosystems, Foster City, CA) using the POP4 polymer and dye
set E5. Results were analyzed using the software GeneMapper ver. 3.5.
Since KCNQ1 is transcribed in an anti-sense direction and from the
opposite strand toKCNQ1OT1 detection of the KCNQ1 nascent transcript
with this assay is a possibility. However, detection of the KCNQ1unspliced RNA by single-nucleotide primer extention or by direct se-
quencing of cDNA has never been reported [2, 22, 23, 38, 45–47].
4.11. Array design
Arrays representing 33 megabases of the p-terminal segment of
chromosome 11 were generated by DNA synthesis by maskless photo-
lithograpy [48] (Nimblegen, Iceland). Representation of the ﬁrst 33
megabases of sequence from chromosome 11 for array CGH and DNA
methylationwas performed as follows. Array CGH probeswere selected
from only non-repetitive DNA. Using the RepeatMasker track from the
UCSC genome browser coordinates chr11:1–33,000,000 (http://
genome.ucsc.edu, Human Genome Build 36.1 (NCBI) March 2006 ver-
sion, with HG18 annotation track) all repetitive sequences
(15,727,426 nucleotides) were removed from our design. The remain-
ing 17,272,574 nucleotides were represented by 300,000 isothermal ol-
igonucleotides of approximately 50 nucleotides in length (feature).
Each feature was checked for uniqueness against the genome to mini-
mize possible cross-hybridization. The 300,000 features gave an aver-
age resolution of 58 bp between probes.
The remaining ~85,000 features were designated for HELP (HpaII
tiny fragment Enrichment by Ligation-mediated PCR) [29]. First, an in-
silico digest was performed with HpaII (CCGG) for the ﬁrst 33 mega-
bases of chromosome 11, excluding repetitive sequences, and selection
of fragments between 50 and 2000 bpwere retained for probe design. A
50-mer oligo was then designed every 5 base pairs and tested for
uniqueness against the genome (www.ncbi.nlm.nih.gov/blast). Eight
oligonucleotides were then selected to represent each HpaII fragment
based on a selection algorithm that counts the number of oligos per
HpaII fragment and give penalties for degree of overlap of each oligo
in a sliding 15-mer window and for stretches of G's or C's longer than
3 nucleotides or A's and T's longer than 5 nucleotides. After the ﬁrst
oligo is selected the remaining oligos are positioned to achieve an opti-
mal spacing of oligos across the entire HpaII fragment.
4.12. Array CGH hybridization
Genomic DNA samples for INV1U, INV1A, T1U and T1A were frag-
mented by sonication to a size range of 500-2000 bp. For labeling, 1 ug
was denatured at 98 °C in the presence of Cy3 and Cy5-labeled
oligonucleotides and random primers. The denatured samples were
chilled on ice. The samples were then incubated with 100 units (exo-)
Klenow fragment and dNTPs (6 mM each) at 38 °C for 2 h. After
termination of the reaction with 0.5 M EDTA samples were precipitated
with isopropanol and resuspended in water. The translocation and
inversion samples were hybridized with Cy5 and the reference sample
with Cy3. The reference sample consisted of a pool of six male
individuals (Promega, Madison WI). Samples were then hybridized to
the array and scanned at the Nimblegen Service Laboratory.
4.13. Isoschizomer representations
Ten μg of DNA from CNL1, CNL2, CNF1, CNF2, INV1U, INV1A, INV2A,
T1U and T1A were digested using HpaII or MspI. After cleaning the
DNA by phenol-chloroform extraction and rehydration in TE pH 8.0
one-tenth of the sample was incubated with T4 DNA ligase with the fol-
lowing primers, HELP 1–5′-CGACGTCGACTATCCATGAACAGC-3′, HELP—
2–5′-GTACTTGTCGGC-3′. The mix was incubated for 5 min at 55 °C and
then the temperature was gradually reduced to 4 °C over 1 h. At this
time an additional unit of T4 DNA ligase was added and the reaction
was incubated overnight at 16 °C.
To perform ligation-mediated polymerase chain reaction (LM-PCR),
1/50 of the MspI or 1/25 of the HpaII sample was ampliﬁed using the
HELP-1 oligonucleotide. An extension for 10 min at 72 °C was followed
by 20 cycles of 95 °C for 30 s and 72 °C for 3 min. A ﬁnal polishing step
was performed at 72 °C for 10 min. The products of the ampliﬁcation
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instructions and then quantitated by spectrophotometry.
Each of the translocation and inversion samples were labeled for
microarray with Cy3 or Cy5-conjugated olignucleotides and random
primers. The HpaII and MspI representations were cohybridized to
the microarray in the NimbleGen Service Laboratory and scanned to
quantify the ﬂuorescence at each oligonucleotide on the microarray.
4.14. Array CGH data analysis
Copy number analysis was performed by importing the array CGH
data from each test and reference sample into R (www.r-project.com)
and applying the normalize.qspline function [49] from the bioconduc-
tor package (www.bioconductor.org). Log2 ratios for each probe were
averaged into 800 bp, 1600, and 4000 bp segmentation ﬁles to quan-
titate the presence of gains or losses for the ﬁrst 33 megabases of
chromosome 11.
4.15. HELP methylation data analysis
Visual analysis of each cohybridization was performed to ensure
that uniform signals were observed on themicroarrays. Each restriction
fragment generated by theHELPmethodwas represented by 8 oligonu-
cleotides on the microarray. The median signal intensity was calculated
for each fragment. Normalization of signals was performed as described
previously [29] to center log ratios across the entire array.
In order to visualize global patterns of DNA methylation in each of
the samples methylation ratios were averaged into 0.5 megabase bins
for the ﬁrst 33 megabases of chromosome 11. Lymphoblast and ﬁbro-
blast samples were analyzed separately so as to minimize inherent tis-
sue speciﬁc differences in methylation. Each DNAmethylation signature
for individual patient samples were plotted against the average of the
controls subtracted from each sample. Thismanipulation then represents
DNAmethylation in thepatient samples as a deviation from the control
average. Deviations below zero represent greater methylation in pa-
tient samples and deviations above zero represent less methylation
in patient samples.
Heat maps for methylation data were created using the Integrative
Genomics Browser (http://www.broad.mit.edu/igv/index.html). A red-
blue color spectrum was generated for each methylation data point
with red representing unmethylated regions, white representing differ-
ential methylation and blue representing methylated regions.
Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.ygeno.2011.10.007.
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